Delaware pharmacy law questions often turn on who may act, what authority supports the action, and which record must show what happened. Start by identifying the person or facility involved, then distinguish a valid prescription from a safe and lawful dispensing decision. A prescriber’s authority does not remove the pharmacist’s duty to evaluate the order, and a pharmacy permit does not give every employee the same clinical duties. This guide follows those decisions from licensure and personnel roles through prescribing, dispensing, and pharmacy operations. Its examples use stated facts where a numerical limit or detailed rule depends on current law. For Delaware practice, apply the prevailing state requirements together with applicable federal law.
Licensure/Personnel
1. Choosing a Delaware licensure route
Start with the applicant’s history, not the examination they hope to schedule. Delaware’s licensure guidance distinguishes examination, score transfer, and license transfer. Examination generally fits a candidate who has not passed the NAPLEX and wants Delaware as the primary eligibility state. Score transfer fits a candidate who requested that a NAPLEX score go to Delaware through the stated route and timing. An applicant already licensed in another jurisdiction generally uses license transfer. For that route, Delaware evaluates current licensure, standing across jurisdictions, examination history, and other statutory qualifications. Prior licensure does not itself establish knowledge of Delaware law: the transfer statute still calls for a passing jurisprudence examination. Classify the route first, then list the evidence and examination steps attached to it. A score sent to Delaware is an examination result, not a Delaware license.
Worked example: Mara has practiced under an active Pennsylvania pharmacist license for six years and now seeks a Delaware license. She applies through license transfer because she is already licensed elsewhere. Her Pennsylvania license supports the application but does not itself authorize Delaware practice or remove Delaware’s jurisprudence examination requirement. She must complete the transfer application and satisfy the remaining Delaware criteria before practicing.
Watch the distinction: Do not call every applicant who must take the MPJE an examination applicant. The route turns on prior licensure and score history; jurisprudence testing can also be required for transfer.
2. Education and experience evidence
Separate permission to sit for an examination from proof sufficient to issue a license. Delaware’s examination pathway requires registration with NABP plus the DELPROS application, fee, and education evidence before the Board can authorize testing. A graduate supplies the applicable graduation certificate or foreign-graduate credential. A student who has completed graduation requirements but has not yet graduated may use an official school letter for examination eligibility. That letter has a limited purpose; the final education evidence is still needed for licensure. Issuance also depends on the required examinations, approved practical experience, background checks, and other qualifications. For examination or score-transfer applicants, the Board page states a 1,500-hour approved experience requirement and identifies school, preceptor, and other-board documentation routes. A sound application review therefore asks two questions in sequence: can this person test, and can this person be licensed?
Worked example: A Delaware applicant has completed every degree requirement, but the university has not issued the graduation certificate. The university sends the Board an official letter confirming completion, and the applicant registers with NABP and files the application and fee. The letter can support authorization to test. Before license issuance, the Board must receive the applicable final education evidence and the required experience and other materials.
Watch the distinction: Authorization to test is not a provisional pharmacist license. Passing examinations while graduation or experience evidence remains outstanding does not permit independent pharmacy practice.
3. Intern registration and supervision
Delaware distinguishes a pharmacy intern from a student working within an approved college-coordinated practical experience program. The student exception applies when the student participates in that program under a licensed pharmacist’s direct supervision. Outside that setting, a learner earning Delaware internship experience needs the applicable intern registration or permit before working as an intern in a Delaware pharmacy. The distinction depends on the activity’s basis and supervision, not merely the learner’s enrollment in pharmacy school. Direct supervision also does not turn a technician into an intern or give a learner an unrestricted pharmacist license. Ask whether the work is part of the approved college program, who supervises it, and whether separate hours are being earned through pharmacy employment. Delaware’s application guidance describes how experience is documented, including school practical-experience forms and preceptor affidavits. Hours should be traceable to the appropriate route and supervisor.
Worked example: Lena completes a college-coordinated rotation under a licensed pharmacist’s direct supervision. That supervised student activity fits the statutory exception. After the rotation, she takes a separate Delaware pharmacy position to earn remaining pre-licensure hours. For that employment, she needs the applicable intern permit, and her preceptor must document qualifying experience through the Board’s process.
Watch the distinction: Being a pharmacy student does not create a blanket exemption from intern registration. The exception is tied to an approved college-coordinated experience and direct supervision.
4. Foreign-trained pharmacist pathway
A foreign pharmacy degree and the credential Delaware requests for foreign graduates serve different evidentiary roles. The diploma establishes an educational history, but the Delaware examination or score-transfer application page directs graduates of schools outside the United States to submit a Foreign Pharmacy Graduate Examination Committee certificate. The licensure statute separately points foreign-trained applicants to education requirements in Board rules. Practical experience must also be documented; the Board’s examination pathway identifies approved internship hours and acceptable evidence from schools, preceptors, or another jurisdiction’s board. Follow the applicant’s actual route before assembling documents. A previously licensed pharmacist seeking transfer is evaluated under the transfer statute, which also addresses foreign-graduate examination evidence but does not impose the initial applicant’s practical-experience requirement. A missing credential is a documentation and qualification issue, not something a passing MPJE score repairs.
Worked example: An applicant educated abroad sends Delaware a pharmacy diploma, an MPJE score, and a personal spreadsheet of work hours. On the examination route, those items leave gaps: the stated foreign-graduate evidence is the applicable FPGEC certificate, and qualifying experience needs approved documentation. The applicant should have the required credential and experience records submitted through the specified channels before expecting license issuance.
Watch the distinction: A foreign diploma does not substitute for the foreign-graduate evidence Delaware specifies. Likewise, undocumented work experience cannot be assumed to meet the approved internship requirement.
5. License transfer and prior discipline
License transfer begins with proof of current licensure in good standing, but Delaware examines more than the status of one active license. Its transfer statute considers the applicant’s standing in every jurisdiction where the applicant is or was licensed and incorporates criteria concerning prior administrative penalties, present ability to practice safely, and substantially related criminal matters. A prior disciplinary order is relevant evidence, yet the statute allows the Board to review documentation or hold a hearing to decide whether that penalty warrants denial. Distinguish three facts: an active license, an underlying disciplinary finding, and Delaware’s decision about that finding. The Board cannot assess the second fact from an “active” status label alone. A transfer applicant should disclose the history accurately and supply the underlying order and disposition. Concealing it creates a separate credibility and qualification concern.
Worked example: Noah holds an active pharmacist license in another state and applies for Delaware transfer. A prior probation order concerned a recordkeeping violation and has since ended. His active status does not erase the order, and the order does not automatically prove Delaware must refuse him. The Board reviews the documented facts against Delaware’s criteria and decides whether he qualifies.
Watch the distinction: Do not equate “active” with “never disciplined,” or treat every past sanction as automatic denial. Delaware’s decision requires examination of the record and applicable criteria.
6. Renewal and continuing competence
Delaware pharmacist licenses renew biennially. Renewal includes the appropriate fee and an attestation that the pharmacist has met the Board’s continuing education requirements. Think of continuing education as one condition of renewal, not as an independent source of practice authority. The license’s current status controls whether the pharmacist may practice: Delaware prohibits practice while a license is expired, inactive, suspended, or revoked. Before a shift, a pharmacist should be able to establish an active license; a pending renewal or completed education transcript alone is insufficient. If the license has lapsed, the elapsed time affects the restoration path and the evidence required. The supplied statute identifies distinct paths for lapses of more than one but less than four years and for lapses longer than four years. Do not infer an exact continuing education hour count from the statute’s general reference to Board requirements.
Worked example: A pharmacist finishes the required continuing education in May but misses the license renewal deadline. In June, the employer schedules the pharmacist to verify prescriptions. The education record shows progress toward renewal, but the expired license bars practice. The pharmacist must complete the applicable renewal or reinstatement steps and confirm active status before performing pharmacist duties.
Watch the distinction: Continuing education completion and license renewal are separate facts. A pharmacist cannot keep practicing during expiration merely because the education requirement has been met.
7. Lapsed versus inactive licenses
A lapsed license and an inactive license begin differently, so their restoration routes differ. A lapse follows failure to keep the license renewed. For a lapse longer than one year but shorter than four years, Delaware specifies a late fee, continuing education proof, criminal-history submissions, and a review of discipline in other jurisdictions. A lapse longer than four years adds proof of retaking and passing the MPJE. Inactive status is requested in writing and may last up to four years. Reactivation within that period requires written notice, continuing education, the applicable fee, criminal-history submissions, and the disciplinary review. If inactive status persists beyond four years, the person must reapply and pass the MPJE. Begin by identifying the status and its start date, then select the statutory path. Neither inactive nor lapsed status permits practice while restoration is pending.
Worked example: Priya let her Delaware license lapse five years ago and now wants to return. Five years is longer than four, so the longer-lapse reinstatement route applies. She needs the specified fee, education proof, background-check submissions, disciplinary review, and a new passing MPJE result. Paying a late fee alone does not restore her authority to practice.
Watch the distinction: Do not use the inactive-status reactivation checklist for every former licensee. A lapsed license follows its own elapsed-time rules, and a long lapse requires another MPJE pass.
8. Pharmacist-in-charge responsibility
Delaware ties each pharmacy’s management to a pharmacist-in-charge who holds a Delaware pharmacist license. The pharmacy-licensing statute allows only one pharmacist-in-charge for each pharmacy and only one pharmacy per pharmacist-in-charge. This creates identifiable operational accountability for compliance with pharmacy, controlled-substance, and other applicable requirements. It does not mean the pharmacist-in-charge personally performs every dispensing act or absorbs another pharmacist’s professional judgment. A dispensing pharmacist remains responsible for the clinical and certification tasks that the law assigns to authorized personnel. When analyzing a staffing problem, separate facility management from responsibility for the prescription at hand. Ask who is designated for the location, whether that person is qualified and limited to one pharmacy, and which pharmacist actually reviewed and certified a particular order. A business cannot solve a designation gap by naming one person across two separate stores.
Worked example: A company names the same Delaware pharmacist-in-charge on applications for two separate community pharmacies. The statute permits one pharmacist-in-charge per pharmacy and one pharmacy per pharmacist-in-charge, so that designation cannot serve both locations. The company must designate a different qualified pharmacist-in-charge for one site. Each pharmacist dispensing at either site still retains responsibility for that pharmacist’s own clinical work.
Watch the distinction: The pharmacist-in-charge is not a universal substitute for the dispensing pharmacist. Facility oversight does not erase each authorized professional’s duty to review and certify work performed.
9. Reserved clinical acts
Delaware identifies clinical and legal acts that may be performed only by a pharmacist or another person within a statutory exception, such as a qualifying intern or directly supervised student in an approved college program. These include prescription certification, drug utilization review, patient counseling, and drug information requiring clinical or technical knowledge. The statute also addresses receiving new verbal orders without recorded backup and contacting prescribers about interpretation or therapy changes. A technician’s experience can improve accuracy and help detect problems, but it does not change the technician’s legal category. The practical sequence is to let the technician gather, enter, or prepare information within permitted supervision, then route clinical decisions to authorized personnel. If a technician notices an interaction, that observation is valuable; the authorized reviewer must assess its significance, resolve it, and certify the order as required.
Worked example: A technician preparing a prescription sees that the new drug may interact with a drug in the patient’s profile. The technician flags the issue and pauses preparation. The pharmacist assesses the interaction, considers the patient’s therapy, contacts the prescriber if needed, and decides whether the order can be certified. The technician’s alert does not itself complete drug utilization review.
Watch the distinction: A technician who identifies a clinical risk has helped the pharmacist, but has not acquired authority to perform the formal review, counsel the patient, or certify the prescription.
10. Delegation and direct supervision
Delegation is task-specific. Delaware allows other responsibilities to be delegated to certified pharmacy technicians or technicians under a pharmacist’s direct supervision, while reserving defined clinical acts to pharmacists and other statutorily authorized people. Entering prescription data, retrieving stock, and preparing a fill can be preparatory work when supervision and the applicable workflow permit it. Deciding whether therapy is appropriate, resolving an ambiguous order with a prescriber, counseling, and certifying the prescription require the authorized professional. Use a three-step decision: identify the exact act, decide whether it involves protected clinical judgment, then confirm the worker’s status and supervision. A computer entry is evidence of what was entered, not proof that the order was clinically reviewed. A supervising pharmacist must also ensure that delegated work reaches the required professional check before release.
Worked example: A directly supervised technician enters a new prescription and selects the stock bottle. The entered strength matches the order, but the patient profile shows a possible allergy. The technician stops and alerts the pharmacist. The pharmacist verifies the history, resolves the risk, and performs the required certification before dispensing. Correct data entry cannot replace those professional decisions.
Watch the distinction: Do not decide delegation by job title alone or by how often someone has performed a task. The nature of the act and the required supervision control.
11. Impairment and safe practice
An impairment concern is first a patient-safety problem and then a professional-process problem. Delaware’s licensure criteria and discipline grounds address conditions that impair judgment or the ability to practice with reasonable skill, competence, and safety. Observe and record concrete signs, such as repeated unexplained errors or inability to complete verification, rather than diagnosing a cause from appearance. If safe practice is in doubt during a shift, stop the affected person’s clinical duties, secure qualified coverage, and protect prescriptions already in progress from unreviewed release. Follow applicable reporting and assistance procedures with confidentiality appropriate to the situation. An allegation may require investigation; it is not itself a final Board finding. The key distinction is between an immediate operational response to a credible risk and a disciplinary determination made through the governing process.
Worked example: During an evening shift, a pharmacist repeatedly loses track of orders and nearly releases the wrong strength. The manager removes the pharmacist from verification duties, asks another qualified pharmacist to cover, and checks work in progress for errors. The manager documents the observed behavior and follows the applicable reporting process. No one needs to label the cause before protecting patients.
Watch the distinction: Do not wait for a formal diagnosis or Board order before responding to an immediate dispensing risk. Also, do not treat a coworker’s suspicion as a proven disciplinary violation.
12. Individual discipline grounds
A discipline ground describes conduct that permits a case to be brought; a sanction is the consequence the Board selects after the required process and findings. Delaware lists grounds including fraudulent licensure conduct, allowing another person to use a pharmacist license, negligent or incompetent practice, certain related criminal conduct, impairment affecting safe practice, and violations of governing law or ethics rules. After a hearing and a finding, the Board may choose among reprimand, probation with conditions, suspension, revocation, and an administrative penalty, alone or in combination. A scenario should therefore be analyzed in stages: identify the alleged act, match it to a statutory ground, ask what evidence and procedure establish it, then consider possible sanctions. The statute does not make every instance of a listed act produce the same penalty. Prior discipline elsewhere may also matter when its underlying facts meet Delaware’s criteria.
Worked example: A pharmacist lends a license credential to an unlicensed coworker, who uses it to appear authorized. Allowing another person to use the license is a Delaware discipline ground. The Board must determine the facts through its process before imposing a sanction. Depending on its findings, available sanctions include a reprimand, probation, suspension, revocation, or an administrative penalty.
Watch the distinction: Naming a discipline ground does not identify the final penalty. The Board must establish the violation and select a sanction under the governing process.
13. Notice, hearing, and appeal
For ordinary individual-license discipline, Delaware requires proper notice and an opportunity to be heard before the Board disciplines a pharmacist or limits practice. A complaint is investigated; if a statutory ground is pursued, the hearing follows the state’s administrative procedures. The Board then makes findings and issues a decision. A licensee who disagrees may appeal to Superior Court within the statutory period measured from mailing of the decision. Keep that sequence distinct from any separate temporary-suspension procedure, which has its own safeguards. In an examination scenario, ask what has happened so far: complaint, investigation, notice, hearing, Board decision, or appeal. A reported allegation may justify prompt safety measures at work, but it does not itself establish professional misconduct. The Delaware pharmacy statute supplies the individual-license grounds and procedural framework.
Worked example: A patient files a complaint alleging that a pharmacist negligently filled a prescription. The complaint triggers investigation, not automatic suspension. If the Board pursues ordinary discipline, it must give proper notice and a hearing opportunity before deciding whether the facts establish a ground and what sanction follows. The pharmacist may then use the statutory appeal route if dissatisfied with the decision.
Watch the distinction: Do not skip from an accusation to a final sanction. The ordinary process requires investigation, notice, an opportunity to be heard, and a Board decision.
Pharmacist Practice
14. Finding every applicable rule
A lawful prescription or pharmacy act must satisfy every applicable layer of authority. The pre-2027 MPJE competency statements frame questions around prevailing state and federal pharmacy law, with answers given for the jurisdiction where licensure is sought. Start by identifying the act: issuing, receiving, dispensing, administering, transferring, or storing a drug. Then identify the actors and drug category. Test prescriber authority and professional scope, the permitted order or transmission method, required order content, drug-specific restrictions, and the pharmacy’s own obligations. A permitted technology does not validate an unauthorized prescriber; a properly licensed prescriber does not cure an incomplete or inauthentic order. If requirements overlap, the act must satisfy both sets. The general MPJE study guide can help organize the common framework, while the final decision must fit Delaware’s prevailing rules.
Worked example: Assume federal rules permit the electronic transmission used for an order. The case also states that its sender lacks authority to prescribe that drug under the applicable practice rules. The electronic route passes one check, but the prescriber-authority check fails. The pharmacist cannot accept the order for dispensing from that sender merely because the software transmitted it successfully.
Watch the distinction: Do not treat federal permission for a transmission method as permission for every person to prescribe through it. Route, prescriber authority, and drug restrictions are separate checks.
Reference: [1]
15. Prescriber authority for the drug
Prescriber authority is specific to the person, the drug, and the proposed use. Verify the practitioner’s professional license and identity, then ask whether that profession’s scope allows the requested prescribing act. For a controlled substance, consider the applicable controlled-substance registration and any limits attached to it. Patient, drug, strength, and directions may all be present while the issuer still lacks authority. Conversely, a practitioner’s authority for one category does not automatically extend to another. Build the decision in sequence: identify the prescriber, classify the drug, identify the setting and purpose if relevant, and compare those facts with the authority granted to that practitioner. If a credential or registration conflicts with the order, authenticate and resolve the discrepancy before dispensing. The pharmacist’s review concerns the actual authority behind the order, not simply whether the prescription looks complete.
Worked example: A practitioner has an active professional license. In the hypothetical facts, that practitioner is not authorized to prescribe the controlled drug requested. The prescription names a patient, dose, quantity, and directions, but those complete fields do not confer prescribing authority. The pharmacist holds the order and seeks an authorized prescription rather than editing the existing one into validity.
Watch the distinction: A valid professional license is only the first authority check. Scope and any controlled-substance authority must cover the particular drug and act.
Reference: [1]
16. Drug-use restrictions
Some drugs carry dispensing conditions beyond ordinary clinical suitability. A restriction may arise from law, an approved risk-management program, distribution controls, or a condition attached to the product. Identify the exact restriction, the person or entity that must meet it, and the stage at which compliance must be established. Enrollment, authorization, documentation, or a required patient step may be necessary before the drug leaves the pharmacy. This differs from a clinical preference: a pharmacist may weigh a preference during therapeutic review, while a binding program condition must be fulfilled. Do not assume a plausible indication or a prescriber’s signature bypasses the program. Also avoid importing conditions from one drug to another. In a case, use the stated program requirements and ask which prerequisite remains unmet, whether it can be completed, and whether dispensing must wait.
Worked example: A specialist writes a clinically reasonable prescription for a drug in a stated restricted-distribution program. The scenario says the pharmacy must be enrolled, but its enrollment has lapsed. Even though the indication and dose make sense, the program condition is unmet. The pharmacy must restore the required status or arrange a lawful alternative before the product is dispensed.
Watch the distinction: Do not confuse clinical appropriateness with legal or program eligibility. A drug can be appropriate therapy while a required dispensing condition remains unsatisfied.
Reference: [1]
17. Prescriber agents and authorization
A prescriber’s agent may communicate a decision the prescriber has already made through a permitted channel; the agent does not thereby become the prescriber. Separate message transmission from clinical authorization. For a new order, determine who selected the drug, directions, quantity, and refills, then establish that the communicator is accurately relaying those approved terms. If the agent proposes a new dose or adds refills independently, that is a prescribing decision requiring the prescriber’s authorization. Document the identity and role of the caller or sender and preserve the actual terms received. Rules may vary by drug category and transmission route, so an agent’s involvement does not make every verbal, faxed, or electronic order acceptable. When uncertainty concerns what the prescriber approved, contact the prescriber through a reliable channel instead of treating the agent’s guess as an amendment.
Worked example: An office assistant calls in an authorized noncontrolled order for one tablet daily, quantity 30, with no refills. The pharmacist records those terms and the assistant’s role. When the assistant suggests adding three refills because the patient usually receives them, the pharmacist declines to enter them without prescriber authorization. The relayed order remains at zero refills.
Watch the distinction: An agent can relay an authorized order, but cannot create new refill or dose authority by speaking for the office. Verify any proposed change with the prescriber.
Reference: [1]
18. Noncontrolled prescription completeness
Evaluate a noncontrolled prescription as an instruction that must be both attributable to an authorized prescriber and usable for safe dispensing. Identify the patient and prescriber, the intended drug and strength, dosage form when material, directions, quantity, and any refill authorization. Then check whether those elements fit together. A missing or ambiguous direction is more than a data-entry gap because the patient label must communicate how to use the product. “Use as directed” may be meaningful when a separately available, authenticated regimen supplies the direction; without one, it leaves the dispenser to invent therapy. Distinguish clarification from alteration: the pharmacist may resolve uncertainty with the authorized source and document the confirmed terms, but should not silently choose a likely regimen. Finally, compare the order against the patient profile for allergies, duplication, and other clinical concerns before release.
Worked example: An order names the patient, prescriber, drug, and 20 mg strength, but the directions say only “use as directed.” No treatment schedule or separate instruction is available. The pharmacist contacts the prescriber and confirms one tablet by mouth each morning, then records that clarification and labels the medication accordingly. Guessing once daily from prior prescriptions would have been insufficient.
Watch the distinction: A complete drug name and strength do not make an order usable when the regimen is unknown. Do not invent directions to fill a blank label field.
Reference: [1]
19. Verbal orders and accurate transcription
When a verbal order is permitted, the record must reflect the order actually authorized and communicated. Establish the caller’s identity and authority, capture each material term, and use read-back or another reliable confirmation method to catch errors. Compare the confirmed terms with the entered prescription before filling. If the entry differs, correct it with an audit trail that preserves the source and the change; never allow a convenient screen entry to supersede the call. Delaware separately reserves receiving new verbal prescription orders without recorded backup to pharmacists and other people within the statute’s specified exceptions, so personnel status matters as well as the drug’s verbal-order rules. A verbal order also remains subject to prescriber authority, completeness, and clinical review. The central evidence question is what the authorized prescriber actually ordered, not what the transcription happened to say.
Worked example: A permitted verbal order is repeated back as one tablet twice daily, and the caller confirms it. The pharmacy record mistakenly says once daily. Before dispensing, the authorized professional corrects the record to twice daily and documents the correction. For a hypothetical 30-day course, the intended directions mean 2 tablets/day × 30 days = 60 tablets, assuming no other dose changes.
Watch the distinction: Do not resolve a transcription conflict by following whichever version is already in the computer. Confirmed source terms govern, and the corrected record must remain traceable.
20. Electronic, faxed, and written orders
Classify how an order reached the pharmacy before applying route-specific rules. A written original, faxed image, and authenticated electronic prescription may display similar fields, but their origins and permissible uses can differ, especially for controlled drugs. Inspect the route, sender, integrity of the content, and any signs of alteration or missing information. A photograph or screenshot forwarded by a patient is evidence that an order may exist; it is not automatically the authenticated order sent through an authorized prescribing channel. Legibility matters regardless of route. If a fax blurs a strength or an electronic record contains conflicting directions, the pharmacist needs a reliable clarification from the prescriber or other authorized source before dispensing. Document the resolution and retain the order record required for that route. Transmission establishes how information arrived; authenticity and completeness establish whether it can be acted on.
Worked example: A pharmacy receives a fax that clearly names the patient and drug but shows a blurred strength that could be 5 mg or 15 mg. The pharmacist does not choose the more familiar strength. After contacting the prescriber through a reliable number, the pharmacist confirms 15 mg, documents the clarification, and proceeds with the corrected order and clinical review.
Watch the distinction: A document that looks like a prescription is not automatically authentic or complete. The transmission route and every material term must support a defensible dispensing decision.
Reference: [1]
21. Controlled-substance classification
Start with the drug and its current legal schedule, then choose the rules for issuing, receiving, dispensing, and refilling its prescription. A familiar brand name is not enough: identify the active ingredient and formulation, because the classification of a particular product controls the decision. Schedule II has no refill authority under federal controlled substance law. Other schedules have different limits, and a prescriber’s authorization must still be present. An unscheduled drug does not become controlled merely because it has abuse potential. When a question supplies a schedule, use that fact rather than guessing from the drug’s therapeutic class. For Delaware practice, consider applicable state restrictions alongside federal requirements. The MPJE competency statements identify controlled prescription requirements as part of the pharmacist practice scope; they do not supply each drug’s current classification.
Worked example: Assume the case establishes that Drug A is Schedule II and Drug B is Schedule IV. A label for A lists one refill, while B’s record shows one authorized refill remaining. A cannot be refilled: the printed entry cannot create Schedule II refill authority. B may be considered for a refill only after checking the original authorization, dispensing history, elapsed time, and applicable Delaware and federal limits.
Watch the distinction: Treating all controlled drugs as if they share Schedule II rules would wrongly reject some authorized refills. First classify the specific product, then apply its schedule’s rule.
Reference: [1]
22. Controlled-order identifiers
Read a controlled prescription as one linked set of facts. Match the patient’s identity to the intended recipient; identify the prescriber and verify professional authority for the drug; then reconcile the drug, strength, quantity, directions, and date with the communicated order. A controlled substance registration is relevant, but a registration number by itself does not prove that the named practitioner issued this particular prescription or may prescribe outside the practitioner’s professional scope. Inconsistent names, addresses, or registration details call for authentication through a reliable channel independent of the questionable document. Record the resolution so a later reviewer can see why the order was accepted or rejected. Even a technically complete form may fail if the prescriber lacks authority or the order is not genuine. Delaware candidates should make both federal and state authority checks.
Worked example: A prescription names Dr. Lane, but the registration details supplied in the case identify Dr. Chen. The patient, medication, quantity, and directions are otherwise complete. The pharmacist holds the order and contacts the practice through a verified number. If the practice confirms that Dr. Chen issued it, the pharmacist obtains a properly attributable order rather than silently changing the prescriber name.
Watch the distinction: A matching registration number does not cure a conflicting prescriber identity. Authentication concerns who issued the order, not just whether a number appears valid.
Reference: [1]
23. Oral orders and Schedule II emergencies
An oral controlled prescription must fit the rules for its schedule and transmission route. Schedule II ordinarily requires an accepted written or electronic prescription; the federal emergency oral route is a narrow exception for immediate treatment when ordinary prescribing is impractical and no suitable alternative is available. It carries special limits on quantity, pharmacist documentation, and prescriber follow-up. Those conditions must be established from the facts, not inferred from a caller’s use of the word “emergency.” An emergency oral order also does not revive an exhausted prescription or permit a Schedule II refill. For other controlled schedules, an oral route may be available if the authorized prescriber communicates a valid order under applicable rules. Work in sequence: identify the schedule, establish prescriber authority, test the route, capture the actual terms, and resolve any discrepancy before dispensing.
Worked example: An office caller asks for another supply of a patient’s Schedule II medicine and calls it an emergency refill. The prior prescription has already been dispensed. The pharmacist cannot refill it. The pharmacist determines whether a genuine qualifying emergency supports a new oral prescription and, if so, follows that route’s documentation and follow-up requirements; otherwise, a new order through an accepted route is needed.
Watch the distinction: A patient’s urgent need does not itself turn a Schedule II refill into an emergency prescription. The exception concerns a new order under defined conditions.
Reference: [1]
24. Electronic controlled prescriptions
An electronic controlled prescription is an order created, signed, and transmitted through a compliant electronic prescribing process. A photograph, patient email, portal screenshot, or ordinary message may display the same words without carrying the authentication and transmission evidence needed for that route. Check that the receiving system holds the actual transmitted order, that its prescriber and patient information are coherent, and that the prescriber has authority for the scheduled drug. If a displayed image raises a question, use it as a clue for verification, not as the prescription itself. A pharmacy can request a valid order through a lawful channel and document what was received and how the discrepancy was resolved. Electronic appearance is not a substitute for origin, signature, and transmission checks.
Worked example: A patient emails a screenshot showing a Schedule II drug, quantity, and prescriber name. The pharmacy system contains no corresponding electronic prescription. The pharmacist does not dispense from the image. After contacting the prescriber through a verified channel, the pharmacy receives a valid order by an accepted method and evaluates that order before filling it.
Watch the distinction: A screenshot is a copy of displayed information, not proof of a compliant electronic controlled prescription. The pharmacist needs the actual lawful order.
Reference: [1]
25. Schedule II repeat therapy
Separate a refill from a new prescription. A refill dispenses additional medication under the authority of an earlier prescription; federal law does not permit refills of Schedule II prescriptions. A later course of Schedule II therapy therefore requires its own valid prescription, even if a label, software field, or patient profile suggests refills remain. Separate prescriptions may sometimes be issued for future dispensing when all applicable conditions are met, but each retains its own identity and instructions. Do not reinterpret a later prescription as a refill or assume it can be dispensed before any stated earliest-fill condition. Check the prescriber’s current authority, authenticity, date and directions for the particular order presented. This distinction keeps dispensing history, prescriber authorization, and patient instructions aligned.
Worked example: A patient brings a Schedule II bottle labeled “2 refills” and asks for the next month’s supply. The pharmacy record shows only the original prescription. The pharmacist cannot use the printed refill count because Schedule II refill authority is zero. The patient needs a separate valid prescription; if one arrives, the pharmacist evaluates its terms independently.
Watch the distinction: Software or label text cannot grant a Schedule II refill. A new prescription is a separate order with its own validity checks.
Reference: [1]
26. Refill authority for other schedules
For controlled schedules that may be refilled, verify four things before dispensing: the prescriber authorized refills, the number remaining is positive, the prescription is still within its applicable time limit, and no other restriction blocks the fill. Calculate remaining refills from the authorized count minus refills already dispensed, excluding the original fill from the refill count unless the record explicitly defines its fields differently. Reconcile transfers and partial dispensing so the history is not counted twice. A prescriber’s original authorization cannot be enlarged by a pharmacy entry, and a remaining numerical balance does not override an expired prescription. The correct decision comes from both the arithmetic and the legal status of the order. Document any new authorization as an authorized change or new prescription according to the applicable rule.
Worked example: A hypothetical Schedule IV record authorizes two refills. The original fill was dispensed, followed by refill 1 and refill 2. Remaining refills equal 2 authorized minus 2 used, or 0. Even if the prescription is otherwise within its permitted time period, another fill needs new prescriber authority recorded through an acceptable process.
Watch the distinction: Counting the original dispensing as a refill would produce the wrong balance. Conversely, a positive balance alone does not establish that the prescription remains legally usable.
Reference: [1]
27. Clarifying an issued order
When parts of an issued prescription disagree, first identify the exact conflict and its possible clinical consequences. A strength mismatch may affect the selected product, number of dosage units, total dose, and label. The pharmacist should compare available records but must not turn an inference into an undocumented prescriber decision. Contact the authorized prescriber or an appropriate authorized channel, read back the disputed terms, and record who clarified them and when. If the proposed change exceeds what may lawfully be amended on that prescription, obtain a new order through an accepted route. Controlled prescriptions can have narrower alteration rules than noncontrolled ones. The final product and directions must reflect the authenticated instruction, and prospective review should use that corrected version. A mathematically equivalent dose does not settle formulation or dosing intent.
Worked example: The strength field says 10 mg tablets, while the directions say “take two 5 mg tablets daily.” Both yield 10 mg per day, but the intended tablet strength and quantity differ. The pharmacist confirms that the prescriber intended one 10 mg tablet daily, records the authorized clarification, and labels one tablet daily. If that change cannot lawfully be made, the pharmacist obtains a new order.
Watch the distinction: Equal total milligrams do not make conflicting order terms interchangeable. Tablet count, formulation, quantity, and patient directions still need an authenticated resolution.
Reference: [1]
28. Institutional drug orders
An inpatient medication order directs treatment within an institution’s care system. Its prescriber authority, pharmacy review, administration record, and medication custody are evaluated within that framework. A community prescription instead authorizes dispensing a drug to an ultimate user for use outside the institution. The same medicine can move between these pathways, so classify the transaction by who holds and administers the drug, where care occurs, and which record governs the dose. An inpatient order may identify a patient, drug, dose, route, and timing without becoming a retail prescription. If a patient is discharged with medication to use at home, the discharge supply or outpatient prescription needs its own lawful basis and labeling. Avoid applying retail refill assumptions to a nurse-administered hospital dose.
Worked example: An admitted patient has an order for a nurse to administer 2 mg intravenously at 08:00. The hospital pharmacy verifies the order and supplies the dose within the inpatient system; the nurse documents administration. This is not a retail refill. If the patient later needs tablets at home, the discharge arrangement must support that separate supply.
Watch the distinction: Seeing a patient name and drug on an institutional order does not automatically make it a community prescription. Follow the actual custody and administration pathway.
Reference: [1]
29. Drug administration roles
Separate preparation from administration. Selecting a product, preparing a dose, verifying its clinical appropriateness, giving it to the patient, and documenting the administration can involve different people with different authority. Training for one step does not grant authority for the next. For a proposed administration, identify the drug and patient, the practitioner’s legal scope, any required prescription or protocol, eligibility and contraindications, and the record that must show what was given. A pharmacist must also ensure that any delegated preparation stays within supervision and role limits. Delaware law reserves clinical and technical pharmacy acts to pharmacists, interns, or qualifying supervised students while allowing other responsibilities to be delegated under direct pharmacist supervision. The relevant question is who may perform each act, not whether everyone on the team understands the workflow.
Worked example: A technician is trained to prepare a vaccine dose under pharmacist supervision, but the stated protocol authorizes only the pharmacist to administer it. The technician may carry out permitted preparation. The pharmacist checks the patient and order, administers the vaccine, and completes the required administration record. Technician competence in preparation does not change the protocol’s administration role.
Watch the distinction: Training to prepare a dose is not authority to inject it. Match each step to the person’s legal role and the applicable protocol.
30. Counseling and the offer to counsel
An offer to counsel gives the patient a meaningful opportunity to speak with an authorized professional about medication use. Actual counseling occurs when that discussion takes place; a patient may decline after a proper offer. Evaluate who made the offer, whether the patient could respond, and whether the process allowed a pharmacist to address directions, expected effects, precautions, and questions. A silent handoff or printed leaflet does not itself show that an offer occurred. If counseling happens, tailor it to the prescription and the patient’s needs rather than reciting a fixed script. Delaware’s pharmacist practice statute restricts counseling and other clinical acts to authorized personnel. Record the offer and response accurately so the dispensing record distinguishes an offer, a refusal, and an actual discussion.
Worked example: At pickup, a cashier silently passes over a new prescription. The patient leaves without being asked whether they want to speak with a pharmacist. The record should not say an offer occurred. If the pharmacist instead offers a discussion and the patient declines, document the offer and refusal; counseling itself was not performed.
Watch the distinction: A declined offer is different from a missed offer. The patient’s choice matters only after an authorized, meaningful opportunity to discuss the medicine.
31. Counseling records
Counseling documentation should describe what actually happened. Distinguish an offer, a patient refusal, an attempted but unsuccessful contact, and a completed discussion. When counseling occurs, record clinically important advice or a resolved concern clearly enough for continuity of care, while keeping sensitive information confidential. A checked box cannot replace the conversation, and an entry saying “counseled” should not be used when no patient contact occurred. If a record is wrong, correct it through an auditable process that preserves the original entry and identifies the correction; do not silently rewrite history. The pharmacist’s clinical judgment remains with authorized personnel even when another employee helps route the patient to the pharmacist. Accurate records help later staff understand whether a new question was answered or still needs attention.
Worked example: The profile says “counseled,” but a camera and staff account confirm that no one contacted the patient. The pharmacist flags the inaccurate entry, follows the record correction process, and makes a genuine offer through an appropriate channel. If the patient accepts, the pharmacist discusses the medication and records the significant advice actually given.
Watch the distinction: Documenting counseling does not make counseling happen. A false checkbox creates a misleading clinical record and cannot repair the missed patient interaction.
32. Returned drugs and reuse
A returned product can look intact while its storage history is unknown. Before considering reuse, trace custody: who held it, whether temperature and light conditions were controlled, whether packaging or tamper evidence remained intact, and whether the applicable return or redistribution rule permits that product to reenter stock. A manufacturer seal may address tampering but cannot prove that a patient stored a medicine correctly. Products with special storage needs or uncertain identity present further risk. Keep returned medication separate from saleable inventory while deciding whether it qualifies for a lawful reuse pathway or must be sent for appropriate disposal. Record the disposition so the product cannot accidentally be selected for another patient. The decision is about demonstrated integrity and legal eligibility, not apparent thrift or a patient’s assurance alone.
Worked example: A patient returns an unopened prescription vial after two weeks at home. The cap is intact, but the pharmacy cannot establish the temperature, humidity, or custody during that period. Staff segregate the vial from saleable stock and route it through the applicable return or disposal process. The intact cap alone does not support dispensing it to another patient.
Watch the distinction: An unopened container is not automatically reusable. Packaging condition answers only part of the question; custody, storage, identity, and legal eligibility also matter.
Reference: [1]
33. Privacy and quality response
An error response has two parallel tasks: protect the affected patient and protect the patient’s information. First establish what was dispensed and whether the patient used it, then arrange timely clinical assessment and corrective action through qualified staff. Preserve relevant labels, records, and product so the event can be reconstructed, and document communications and follow-up. Share the minimum necessary information with people who need it for care, investigation, or legally required reporting. Another customer’s curiosity gives no right to the patient’s history. Delaware’s pharmacy records provision expressly preserves confidentiality when records are provided to a patient; the same careful handling supports error review. A useful quality review asks where selection, verification, handoff, or communication failed and changes that step.
Worked example: A patient reports receiving the wrong drug. The pharmacist confirms the label and tablets, contacts the patient about exposure and symptoms, arranges appropriate care, and preserves the dispensing records for investigation. When another customer asks for the patient’s name and medication, staff decline to disclose them. The team shares details only with those handling the patient’s care and error response.
Watch the distinction: Privacy does not prevent necessary patient safety communication. It limits disclosure to appropriate recipients and purposes while the pharmacy investigates and corrects the error.
Dispensing Requirements
34. Legitimate medical purpose
A controlled prescription needs more than complete fields and an authorized signature. The pharmacist has a corresponding responsibility to assess whether it was issued for a legitimate medical purpose within usual professional practice. Look for a coherent relationship among the patient’s condition, drug, dose, directions, prescriber, and available treatment history. An unusual fact is a reason to investigate, not automatic proof of invalidity. Ask the patient clarifying questions, review relevant records and controlled drug history where appropriate, and contact the prescriber when the concern remains. Document facts gathered and the decision. If a material concern cannot be resolved, do not dispense on the strength of the form alone. The review should focus on whether this particular order is valid and safe, not on assumptions about the patient.
Worked example: A controlled prescription is complete, but its directions say daily use while the patient says the prescriber intended one dose only after a procedure. The pharmacist pauses, verifies the treatment plan with the prescriber, and resolves which directions are authorized. Dispensing proceeds only if the confirmed order supports the intended use and other requirements are met.
Watch the distinction: Every required field can be present on an inappropriate order. Facial completeness starts the review; it does not end the pharmacist’s responsibility.
Reference: [1]
35. Investigating diversion signals
Diversion signals are clues that need context. Early requests, multiple prescribers, different pharmacies, or repeated lost-medication claims can reflect misuse, fragmented care, or a legitimate change such as hospitalization. Compare dates, quantities, directions, and the patient’s account; use available prescription monitoring information; and communicate with prescribers when needed to reconcile treatment. Do not label the patient dishonest from one pattern alone, but do not dispense until a material inconsistency is resolved. The record should distinguish what was observed from what was verified and explain the dispensing decision. If the investigation establishes overlapping therapy or conflicting instructions, the pharmacist can seek a coordinated plan or decline the fill when validity remains unsupported. This method protects patients without treating a risk marker as a verdict.
Worked example: A patient presents an early controlled prescription from a second prescriber after reporting a hospital stay. The pharmacist finds a recent fill in the history and contacts the hospital and usual prescriber through verified channels. If they confirm a replacement plan and explain the overlap, the pharmacist evaluates the new order on those facts; if they cannot, dispensing waits.
Watch the distinction: Two prescribers or an early request does not prove diversion. The pattern triggers verification, and the final decision rests on the facts established.
Reference: [1]
36. Noncontrolled prescription transfers
A prescription transfer moves usable prescription information between pharmacies while preserving the order’s identity and dispensing history. The receiving pharmacy needs enough information to identify the patient, prescriber, drug, directions, original authorization, previous fills, and remaining refills. Authorized personnel must communicate and record the transfer under the applicable rules, and both pharmacies must prevent duplicate dispensing from the same authority. Calculate the remaining refill balance using refills authorized minus refills already dispensed; do not count the original fill as a refill. Then check whether the prescription is still valid by time and whether any other limitation applies. A mathematically positive balance does not cure an expired or otherwise unusable order. The transfer record should let another pharmacist reconstruct where the prescription came from and what authority remains.
Worked example: A noncontrolled prescription authorized four refills after its original fill. Pharmacy A dispensed the original fill and two refills. At transfer, 4 minus 2 leaves 2 refills. Pharmacy B records the patient, prescriber, drug, directions, prior dispensing, and two remaining refills, then checks that the order is still valid before dispensing.
Watch the distinction: Copying the original refill count to the receiving pharmacy would allow duplicate use of authority already spent. Transfer the verified remaining balance.
Reference: [1]
37. Controlled prescription transfers
For a controlled prescription transfer, identify the schedule and decide whether the request concerns an original prescription or a refill. Those are different transactions with different conditions. Verify that the prescription is eligible for the proposed transfer, that the participating personnel and systems meet applicable requirements, and that both pharmacies preserve an auditable chain of the original order, prior dispensing, and remaining authority. Federal transfer permissions do not erase Delaware restrictions, and a transferred image is not automatically a lawful transfer record. Schedule II prescriptions have no refills, so a supposed Schedule II refill has no remaining refill authority to move. A separately valid original electronic prescription may raise a different transfer question that must be evaluated under the governing rules. For contrast with another jurisdiction’s preparation materials, keep Maryland MPJE guidance separate from Delaware decisions.
Worked example: A patient asks Pharmacy B to transfer “one refill” of a Schedule II prescription from Pharmacy A. Pharmacy A confirms that the original quantity was already dispensed. There is no refill balance: zero Schedule II refills are legally available. Pharmacy B directs the patient to obtain a new valid prescription for further therapy rather than recording a transferred refill.
Watch the distinction: A request to transfer a Schedule II refill cannot create refill authority. Classify the original and refill status before considering transfer mechanics.
Reference: [1]
38. Prospective drug utilization review
Prospective drug utilization review happens before the medication reaches the patient. Compare the new order with the patient’s medication and allergy history for therapeutic duplication, interactions, dose or duration concerns, contraindications, and patterns suggesting misuse. Judge the clinical importance of a signal rather than treating every software alert equally. Confirm the underlying data: an allergy entry may describe intolerance, a discontinued drug may still appear active, or a dose may reflect a documented treatment change. When a serious conflict remains, hold the fill, contact the prescriber or patient as appropriate, and record the resolution. Delaware law identifies drug utilization review as a reserved clinical act, so a technician may flag a concern but cannot complete the pharmacist’s judgment. The release decision should reflect the verified facts and any authorized change.
Worked example: A new antibiotic triggers an alert for a documented severe allergy. The technician stops preparation and alerts the pharmacist. The pharmacist confirms that the prior reaction involved breathing difficulty, contacts the prescriber, and obtains an alternative order. The original antibiotic is not released, and the allergy and intervention are recorded for future review.
Watch the distinction: Overriding an alert without checking its clinical basis can miss serious harm. The pharmacist must verify the history and resolve a material conflict before dispensing.
39. Prescription Monitoring Program use
A prescription monitoring program has two distinct information flows. Querying it brings prior controlled dispensing information into a current clinical decision; reporting sends the pharmacy’s dispensing data into the program. One action does not perform the other. When reviewing a report, match patient identifiers, dates, drugs, quantities, and prescribers before drawing conclusions. A recent fill may reveal overlapping treatment, an expected discharge supply, or a data error, so reconcile it with the patient and prescribers as needed. When reporting, accuracy and correction of rejected or erroneous submissions matter because later clinicians may rely on that record. The MPJE scope expressly includes both accessing PMP data and reporting to it. A case about whether to dispense asks how the query informs judgment; a case about submission asks whether the pharmacy’s data reached the program correctly.
Worked example: A pharmacist queries a patient’s controlled dispensing history and finds a recent fill from another prescriber. The pharmacist verifies whether it was a hospital discharge supply before deciding on the new order. After any lawful dispensing, the pharmacy still handles its separate data submission duty; viewing the earlier fill did not report the new one.
Watch the distinction: Checking the PMP is not the same as submitting a dispensing record. Treat clinical review and data reporting as separate duties.
Reference: [1]
40. Partial fills and remaining quantity
A partial fill supplies less than the prescribed quantity while leaving a possible balance under the same prescription. Record the authorized total, amount actually dispensed, date, reason or request where relevant, and unfilled balance. Calculate the balance by subtracting all units supplied under that prescription from the authorized quantity. Before supplying it later, check the drug’s schedule, the rule governing that type of partial fill, any applicable time condition, and whether the original order remains usable. A balance is inventory arithmetic, not automatic legal permission. Distinguish a later completion of the same prescription from a refill, which uses separate refill authority. Good records prevent the sum of partial supplies from exceeding the prescribed total. Practice cases in Delaware MPJE questions should be solved in that sequence.
Worked example: A hypothetical prescription authorizes 30 tablets, and the pharmacy supplies 18 tablets. The unfilled balance is 30 minus 18, or 12 tablets. If 7 more are lawfully supplied later, the remaining balance becomes 12 minus 7, or 5 tablets. Each later supply still needs to satisfy the schedule-specific partial-fill conditions.
Watch the distinction: The arithmetic balance alone does not authorize another dispensing. Check the governing partial-fill rule and record each quantity so total supply never exceeds the order.
Reference: [1]
41. Emergency continuity of therapy
When a patient has no refills left, the prior prescription establishes treatment history but supplies no new dispensing authority. First identify the drug and its controlled status, then confirm the last directions, fill date, and remaining quantity. Determine whether interruption poses a meaningful clinical risk and whether the prescriber can be reached promptly. An emergency supply is possible only if an applicable Delaware or federal provision permits it for that drug and situation; its conditions govern the quantity, documentation, and follow-up. If no pathway applies, seek a new authorized order and help the patient obtain timely care. Do not convert an urgent patient need into a routine refill. The MPJE competency statements include exceptions to dispensing and refilling, so practice identifying the source of authority before calculating a supply.
Worked example: A patient has taken a maintenance medication daily for months, but the record shows zero refills. The old label confirms the regimen, not permission for another full fill. The pharmacist checks the drug’s classification, interruption risk, prior dispensing record, and prescriber availability. If a governing emergency provision covers the case, the pharmacist follows its specific supply and documentation conditions. Otherwise, a new prescription is needed.
Watch the distinction: An established therapy does not make an expired or exhausted prescription reusable. Clinical urgency helps explain why an emergency exception might apply; it does not create that exception.
Reference: [1]
42. Patient label essentials
A dispensing label must faithfully turn the authorized order into instructions the patient can act on. Check patient and pharmacy identifiers, the drug and strength, directions, and other information required for the product and jurisdiction. Distinguish tablet strength from the dose taken: a 20 mg tablet split in half delivers 10 mg if the tablet may safely be split. Express the number of tablets, route, frequency, and any meaningful duration clearly. Before release, compare the label with the prescription, selected product, and final container. Resolve ambiguous directions with the prescriber rather than guessing from customary dosing. Auxiliary warnings can add essential handling advice, but they cannot repair an incorrect primary direction. The final check should catch both transcription mistakes and clinically important mismatches, such as an unsuitable dosage form.
Worked example: The authorized order is for one-half of a splittable 20 mg tablet by mouth once daily. The dose is 20 mg × 0.5 = 10 mg each day. A clear direction is, “Take one-half tablet by mouth once daily.” The product description still identifies the 20 mg tablet. “Take 20 mg daily” would double the intended dose and misstate the order.
Watch the distinction: Tablet strength and administered dose are different quantities. Listing the correct strength does not excuse directions that tell the patient to take the wrong amount.
Reference: [1]
43. Packaging and child resistance
Choose packaging by asking two questions: will it protect the drug, and does it meet the applicable child resistance requirement? Moisture, light, temperature, breakage, and contamination can make a convenient container unsuitable. Federal child resistant packaging rules generally apply to covered household prescription drugs, with product-specific exclusions and recognized waiver routes; the precise exception must fit the facts. A patient request for easy-open packaging may qualify, but the request and any documentation should be handled under the governing requirements. A prescriber-directed exception is a separate route and should not be inferred from patient preference. After resolving child resistance, still select a container compatible with the drug and the intended use. For example, a light-sensitive product needs protection even when an easy-open closure is lawful.
Worked example: A patient with limited hand strength asks for an easy-open closure on a new prescription. The pharmacist checks whether a patient-requested exception applies, records the request as required, and selects a suitable container. If the medicine also requires light protection, an easy-open clear vial is a poor choice; an appropriate light-protective package with the permitted closure addresses both needs.
Watch the distinction: An easy-open request concerns the closure requirement, not every packaging safeguard. It does not authorize exposing a moisture-sensitive or light-sensitive medicine to conditions that damage it.
Reference: [1]
44. Products that cannot be dispensed
A printed expiration date assumes the product has remained within its validated conditions. Before dispensing, establish identity, lot, expiry, packaging integrity, storage history, and recall status. Broken seals, unexplained relabeling, contamination, temperature excursions, or uncertain provenance are reasons to separate stock from saleable inventory. Quarantine preserves the product and evidence while a qualified person seeks a manufacturer stability assessment or other reliable disposition. A visual inspection alone cannot prove potency or sterility. If the affected lot was already dispensed, trace it through acquisition and dispensing records and follow the appropriate patient and recall response. The decision is about whether quality can be supported, not whether damage is visible. For temperature-sensitive products, record the actual excursion when known, including time and measured temperature.
Worked example: A refrigerated product was discovered outside its labeled range overnight. Its expiration date is three months away, but no temperature log or stability assessment establishes that it remains usable. The pharmacy quarantines the affected lot, records the known storage history, and seeks a reliable disposition. It does not dispense the units merely because the package looks intact and the date has not passed.
Watch the distinction: Expiration is conditional on proper storage. An unexpired package can be unsuitable for dispensing after an unresolved excursion, damaged seal, recall, or loss of identity.
Reference: [1]
45. Nonprescription product categories
Nonprescription status means a product may be supplied without an individual prescription under its approved conditions; it does not mean unrestricted self-service. Start with the product’s ingredients, labeling, and regulatory category. Some products have age checks, quantity controls, placement restrictions, identification checks, or sales records under applicable law. Others are ordinary shelf products but still require assessment when a patient asks for advice. A combination product must be classified by all relevant active ingredients, not by the least restricted one. Distinguish a legal sale condition from a clinical concern: a product might be lawful to sell yet inappropriate for a patient’s medical history. The pharmacist should verify which rule applies at the time of sale, complete required steps, and advise on safe use without claiming that every nonprescription item follows the same workflow.
Worked example: A customer chooses a nonprescription cold product that the case identifies as subject to behind-the-counter controls. The cashier cannot treat its nonprescription label as permission for an unrestricted shelf sale. The pharmacist checks the applicable sale conditions and product ingredients, completes required verification and records, and then addresses the customer’s symptoms and other medicines before recommending use.
Watch the distinction: “Over the counter” describes prescription status, not a single placement or record rule. A restricted-sale product can still be nonprescription, and clinical suitability remains a separate question.
Reference: [1]
46. Repackaged nonprescription products
Repackaging creates a new immediate container, so the information and protection supplied by the manufacturer cannot simply disappear. Confirm that repackaging is permitted for the product and that the new container preserves its stability. Carry forward the correct identity, strength, directions, warnings, and other required consumer labeling. Preserve a link to the manufacturer lot, original expiration, and repackaging event so a recall can identify affected packages. Any assigned beyond-use date must follow applicable product and packaging rules; it is not automatically the manufacturer’s printed date. Separate look-alike products during the work, verify counts, and check the finished labels against the source container. If a package is intended for consumer self-selection, missing warnings can cause harm even when the active ingredient is correct.
Worked example: A pharmacy divides a manufacturer bottle into smaller nonprescription packs. Each finished pack identifies the product and carries the required use directions and warnings. The repackaging record links each pack to the source lot and date information. If that lot is recalled later, the pharmacy can identify and remove the affected packs. A label showing only the drug name would break both safe-use communication and traceability.
Watch the distinction: A smaller package is not merely a container change. Losing warnings, lot linkage, or required directions can make a correctly counted product unsafe or noncompliant.
Reference: [1]
47. Nonprescription safety and devices
For a nonprescription drug or device, begin with the patient’s intended use and the product’s labeled purpose. Ask about age, symptoms, duration, relevant conditions, allergies, pregnancy when pertinent, and current medicines. Compare ingredients and mechanisms with existing therapy to identify duplication, interactions, or contraindications. Devices also require fit, technique, cleaning, and accuracy considerations; a suitable device used incorrectly may fail. Separate referral decisions from sale restrictions: alarming symptoms call for clinical evaluation, while a restricted category adds a legal transaction step. If a requested item is unsuitable, explain the specific reason and offer an appropriate alternative when possible. Document and escalate clinically significant concerns according to the care setting, especially when the product might mask a serious condition or interfere with prescribed treatment.
Worked example: A patient taking a prescribed medicine asks for a nonprescription product that the case states has a clinically significant interaction with it. The pharmacist confirms the current therapy and intended symptom relief, explains the interaction, and selects a compatible alternative if one fits. If the alternative has a restricted-sale classification, the pharmacy completes those sale steps as well. The interaction decision and the sale rule are separate checks.
Watch the distinction: Nonprescription availability does not establish suitability for a particular patient. A device or drug can be easy to buy yet require counseling, an alternative, or referral.
Reference: [1]
Pharmacy Operations
48. Pharmacy permits by location and type
Facility authority follows the place and type of pharmacy activity. Delaware requires a permit for each pharmacy operated in the state, subject to its stated same-institution, one-location provision for approved sites. A separate out-of-state pharmacy that sends prescription drugs to Delaware patients needs Delaware nonresident authority. Check the legal operator, physical location, service type, and destination before choosing the application route. A corporation’s existing permit does not cover every new storefront, and an individual pharmacist license does not license a facility. The pharmacy application also identifies a Delaware-licensed pharmacist-in-charge and the type of pharmacy license sought. When comparing District of Columbia MPJE rules, keep the destination jurisdiction distinct: Delaware patients trigger Delaware’s nonresident pharmacy provisions.
Worked example: A company plans two unrelated Delaware storefront pharmacies and a third pharmacy across the state line that will ship prescriptions to Delaware residents. The two Delaware locations each require their own permit application. The out-of-state site needs the applicable Delaware nonresident pharmacy license before delivering prescription drugs to Delaware patients. One company name and one pharmacist’s individual license do not replace these facility authorizations.
Watch the distinction: Ownership is not the unit of licensure. A single corporate owner can need multiple location permits, and shipping across a state line can add destination-state authority.
49. Permit changes and closure
Routine renewal continues the same licensed operation through the next licensing period; a change in ownership or an end to business changes the legal basis for the facility license. Delaware pharmacy licenses renew biennially. Its statute says a pharmacy license terminates automatically on ownership change, termination of the pharmacy’s legal existence, or discontinuance of business or professional practice. A permit cannot simply be assigned to a buyer without the Board’s specified conditions and written consent. Plan the transition before the sale: identify the new operator, facility application, pharmacist-in-charge, inventory custody, prescription records, and patient access. A temporary or permanent closure also requires compliance with Board rules. This sequence protects continuity while preventing an unlicensed operator from inheriting authority by possession of keys or stock.
Worked example: An owner sells a Delaware pharmacy to a new corporation while the store intends to remain open. The existing facility license does not automatically follow the assets. The buyer must obtain the authority needed for its operation, and both parties must arrange lawful custody of drugs and records during the transition. Paying the former owner’s routine renewal fee would not cure the ownership change.
Watch the distinction: A permit is legal authority granted to an operator, not a transferable store fixture. A sale or closure requires more than updating the sign.
50. Inspections and facility discipline
An authorized Delaware Board agent may inspect a pharmacy during business hours and review required records, relevant premises, equipment, materials, labeling, and stock within statutory limits. The pharmacy should verify the agent’s authority, provide access, and preserve the records as they exist. Refusing access for an authorized inspection or investigation is itself a stated ground for facility discipline. A finding of a violation is distinct from a sanction: Delaware provides written notice of intended action and reasons, an opportunity to request a hearing, and an appeal route after a decision. The Board may choose among available sanctions according to its findings. Patient information gathered during inspection remains subject to confidentiality requirements. For exam reasoning, separate the inspector’s access, the alleged conduct, and the later disciplinary process.
Worked example: A Board agent arrives during business hours to inspect required dispensing records. Staff verify the agent’s role, preserve the records, and provide lawful access. If the pharmacy instead refuses access, that refusal can become a facility discipline ground. It does not automatically revoke the license: the Board must use the applicable notice and hearing process before imposing an ordinary sanction.
Watch the distinction: An inspection request is not the same as a final discipline order. Compliance with lawful access and the opportunity to contest a later sanction are separate stages.
51. Purchasing from legitimate sources
Prescription stock must enter through a legitimate trading partner and remain traceable through the supply chain. Before accepting an unfamiliar seller, verify its applicable authority and the transaction’s product identifiers, lot information, and accompanying tracing records. Match the shipment to the purchase order, inspect seals and packaging, and investigate mismatches before units become saleable. Suspect product should be segregated while its status is resolved. Price can prompt scrutiny but does not by itself prove illegitimacy; reliable source and product evidence control the decision. Retain acquisition records so a later recall, counterfeit investigation, or inventory reconciliation can follow the product backward. The same logic applies when a pharmacy obtains stock through an intermediary: the intermediary’s paperwork must support the actual physical units received.
Worked example: A new seller offers sealed prescription bottles at a steep discount but cannot provide reliable transaction records. The pharmacy verifies the seller’s authority and requests records tying the lot and quantity to the shipment. Until those facts are established, it keeps the bottles out of saleable inventory. A clean-looking seal does not establish legitimate provenance or allow the pharmacy to trace the units later.
Watch the distinction: A bargain price is a warning cue, not proof of counterfeit stock. Conversely, intact packaging does not substitute for a verified trading partner and traceable acquisition.
Reference: [1]
52. Controlled-drug procurement
Controlled-drug acquisition needs an unbroken record from authorized order through physical receipt and inventory entry. Identify the drug’s schedule first because ordering methods differ; Schedule II procurement has a distinct federal ordering framework, while other controlled schedules follow their applicable requirements. Confirm supplier and purchaser authority, then compare the order, invoice, and actual containers. Record what arrived, including discrepancies, without changing the receipt to match paperwork. Investigate shortages, overages, damage, or broken seals promptly and preserve the original documents. Inventory records should support later reconciliation against dispensing, transfers, and disposal. A discrepancy can reflect shipping error, documentation error, or diversion; the immediate task is to establish the facts and follow any applicable reporting duty, not to assume its cause.
Worked example: A hypothetical controlled-drug order and invoice list 25 bottles, but the sealed shipment contains 24. The physical receipt is 24 bottles; 25 − 24 = 1 bottle missing. The pharmacy records the actual 24, separates the mismatch from ordinary stock posting, contacts the supplier, and investigates the chain of custody. Entering 25 as received would conceal the shortage and distort later inventory.
Watch the distinction: The invoice is evidence of what was billed, not proof of what arrived. Inventory must begin with the physical count and a documented resolution of any difference.
Reference: [1]
53. Distribution versus patient dispensing
Classify a drug movement by its recipient and purpose. Dispensing supplies a medication to an ultimate user pursuant to the applicable patient order. Sending sealed stock to another pharmacy for that pharmacy’s inventory is distribution, even if both sites have the same owner. Distribution requires the authority, transaction documentation, and controlled-drug procedures applicable to the products and parties. A patient prescription label cannot turn a wholesale stock transfer into dispensing. Record the sending and receiving entities, drug identity, strength, quantity, lot information when required, and date so the units remain traceable. If controlled substances are involved, evaluate the schedule-specific transfer or ordering rules separately. The distinction matters because patient profile and counseling duties attach to dispensing, while distribution focuses on authorized trading and chain of custody.
Worked example: Pharmacy A sends ten sealed stock bottles to Pharmacy B, which will place them in its inventory. No named patient receives the bottles, so the movement is distribution. Both sites verify their authority and create the applicable shipment and receipt records. If B later fills an individual patient’s prescription from that stock, that later act is dispensing and needs its own patient-level record.
Watch the distinction: Common ownership does not make a stock transfer a patient fill. Follow the physical recipient and purpose of the movement before choosing records and authority.
Reference: [1]
54. Prescription records and patient access
A dispensing record should allow a pharmacy to reconstruct what was supplied, to whom, when, under whose authority, and by whom. Delaware requires records of prescriptions dispensed or compounded to be retained for at least three years and available to authorized Board agents. A patient’s access request follows a different clock: provide the person’s pharmacy records as soon as reasonably possible, no later than 15 business days, unless an emergency or medical condition calls for immediate production. Verify the requester’s identity and use a confidential delivery method; releasing a copy does not authorize deletion of the underlying record. Keep amendments traceable so corrections do not erase what originally occurred. The Delaware pharmacy records statute supplies these facility duties.
Worked example: A patient requests a copy of dispensing records on Monday. Staff verify identity, retrieve the records, and arrange confidential delivery as soon as reasonably possible. The ordinary outer limit is 15 business days, not 15 calendar days; an emergency or medical condition may require immediate production. The pharmacy retains its own records for at least three years even after giving the patient a copy.
Watch the distinction: Patient access and record retention are separate duties. Sending a copy does not start a new retention period or permit destruction of the pharmacy’s original record.
55. Controlled inventory and accountability
Controlled inventory is a reconciliation of physical units against documented movement. Start with the prior verified count, add receipts and returns to stock, then subtract dispensing, authorized transfers, destruction, and other documented removals. Use consistent units, converting bottles to tablets or milliliters before comparing totals. Count actual stock independently; do not adjust it to make the ledger balance. A mismatch calls for a recount, review of recent transactions, package sizes, access records, and any required loss reporting. Restrict access to authorized personnel and retain a clear audit trail for corrections. For practice, the Delaware MPJE questions can test whether you distinguish expected stock from the observed count. A discrepancy is a fact to investigate, not immediate proof of theft.
Worked example: A hypothetical inventory starts at 100 tablets. The pharmacy receives 40 and documents 65 dispensed, with no other movement. Expected stock is 100 + 40 − 65 = 75 tablets. A physical count finds 73, so the variance is 75 − 73 = 2 tablets short. Recount, inspect transaction records, and document the investigation rather than silently changing the opening balance.
Watch the distinction: A ledger balance is a prediction, not a physical count. Changing a receipt or dispensing entry without evidence hides the variance instead of explaining it.
Reference: [1]
56. Storage and hazardous-drug handling
Ordinary storage controls protect identity and potency through appropriate temperature, humidity, light protection, security, and stock rotation. Hazardous drugs add worker and environmental protections because exposure can occur through spills, aerosols, contaminated surfaces, or waste. Determine hazardous status before handling, then select trained personnel, suitable protective equipment, containment, cleaning, and disposal methods for the task and dosage form. A damaged package should be isolated from general stock and assessed as a potential exposure event. A spill response addresses people and surfaces as well as product loss; returning a leaking unit to inventory solves neither problem. Keep handling instructions accessible and document training and incidents. If the drug also requires refrigeration or controlled-substance security, those requirements operate alongside hazardous-drug safeguards.
Worked example: A carton of hazardous-drug vials breaks in a general storage area. Staff restrict access and alert personnel trained for the facility’s spill response. They use the appropriate containment and protective equipment, manage contaminated material through the applicable waste stream, and document exposure and stock loss. The remaining intact stock is assessed separately. Sweeping up glass and returning the leaking carton to a shelf would leave contamination unresolved.
Watch the distinction: Hazardous classification concerns exposure during handling, not just whether a medicine is safe for a patient. Ordinary stock cleanup may spread contamination.
Reference: [1]
57. Delivery and shipping controls
Delivery extends the dispensing chain beyond the counter, so verify the correct patient and address, protect the package, and preserve access to a pharmacist for questions. Match shipping method and packaging to the drug’s labeled conditions; a temperature-sensitive product may need qualified insulation, monitoring, or a different delivery plan. Record handoff and investigate failed or delayed delivery before assuming the patient received usable medication. Delaware adds a specific notice for a licensed nonresident pharmacy when a prescription drug is not personally hand delivered to the ultimate user. The notice in the shipping container must alert the patient to possible effects of extreme heat, cold, or humidity and provide access to a local or toll-free telephone service staffed by a registered pharmacist. That notice does not replace actual product protection.
Worked example: A licensed nonresident pharmacy mails a refrigerated prescription to a Delaware patient. It selects shipping conditions that can maintain the product’s required range and includes the Delaware notice about environmental exposure and pharmacist telephone access. If tracking later shows a prolonged delay and temperature integrity cannot be established, the pharmacy assesses the shipment before treating delivery as complete. The notice alone cannot prove the drug remains fit to use.
Watch the distinction: Shipping a correct label is not enough. Patient identity, product condition, pharmacist access, and Delaware’s nonresident shipping notice are distinct delivery checks.
58. Drug product selection
Product selection begins with the prescribed drug and the precise substitution authority that applies. Compare active ingredient, strength, dosage form, route, and release characteristics; then evaluate recognized equivalence, prescriber restrictions, patient-specific concerns, and any notice or record duties. Same ingredient alone is insufficient when delivery rate or route differs. A lower price can inform the choice only after legal and therapeutic criteria are met. For a biologic or another specially regulated category, use the applicable product-specific substitution framework rather than assuming ordinary generic rules apply. If the authorized order is ambiguous, clarify before selection. Document the product actually dispensed so later refills, recalls, and adverse-event review identify the exact item. The patient should understand any appearance or administration change that could affect use.
Worked example: An order specifies an extended-release tablet. The shelf holds a cheaper immediate-release tablet with the same active ingredient and milligram strength. The release mechanism changes how quickly drug becomes available, so price and ingredient match do not establish an acceptable substitution. The pharmacist obtains the prescribed formulation or an authorized change, then records the exact product supplied and explains any legitimate switch to the patient.
Watch the distinction: Equal milligrams do not guarantee equal therapy. Formulation, route, and release pattern can make two products unsuitable substitutes despite matching active ingredients.
Reference: [1]
59. Compounding decision and controls
Classify a preparation along two independent axes before choosing controls: sterile versus nonsterile, and hazardous versus nonhazardous. Sterile preparations need controls against microbial contamination, particulates, and endotoxin risk where relevant; nonsterile preparations still need suitable ingredients, equipment, calculations, uniformity, and labeling. Hazardous status adds containment, protective equipment, cleaning, and waste controls regardless of whether the product is sterile. Assess whether compounding is appropriate for a specific patient need, confirm formula and ingredient quality, calculate quantities, and assign a justified beyond-use date under the applicable standards. Document each ingredient lot, process, checks, and responsible personnel. An injectable and a topical preparation may share an active ingredient but differ radically in environment, technique, route safety, and final verification.
Worked example: A prescriber requests an injectable preparation and a topical cream containing the same active ingredient. The cream follows applicable nonsterile controls, while the injection needs sterile preparation and verification appropriate to its route. If the ingredient is hazardous, both workflows also require hazardous-drug safeguards. The compounder records ingredients, calculations, lot numbers, and checks separately; one formula or beyond-use date cannot simply be copied to the other.
Watch the distinction: Sterility and hazardous status answer different questions. A preparation can be sterile and hazardous, nonsterile and hazardous, or neither; one control set does not replace the other.
Reference: [1]
60. Central processing and central fill
Central processing divides prescription tasks between cooperating pharmacies; central fill specifically places preparation or filling at a site different from the pharmacy that receives or serves the patient. Map the workflow before a prescription moves: which site accepts the order, verifies prescriber and patient information, conducts clinical review, enters data, fills and labels the product, performs final release, provides counseling access, and maintains retrievable records. Each task must be performed by personnel authorized for it under the applicable arrangement. Shared software does not erase responsibility or make an unchecked handoff safe. Use identifiers and audit trails so both sites can trace the order, product, pharmacist actions, shipment, and correction. If a discrepancy appears, stop the handoff and resolve it before release to the patient.
Worked example: Pharmacy A receives a patient’s prescription and Pharmacy B packages the medicine for shipment. Their authorized workflow assigns A the intake and clinical review, B the product preparation and designated final checks, and a clear method for counseling and delivery. Both records identify the order and work performed. If B finds a strength mismatch, it pauses filling and sends the discrepancy back for resolution before shipment.
Watch the distinction: Sending data to a central site does not transfer every legal duty automatically. The arrangement must identify authorized people, review points, patient communication, and records.
Reference: [1]
Official references and further reading
- Current MPJE competency statements (before March 2027)
- Pharmacist Licensure by Examination or Score Transfer - Division of Professional Regulation - State of Delaware
- Delaware Code Online
- Delaware Code Online